BRCA2 and Familial prostate cancer: Current guidelines recommend clinical breast examinations beginning at ages 30-35 years and suggest mammographic screening on an individual basis, whereas clinical prostate cancer screening, particularly for BRCA2 carriers, is recommended from ages 40 to 45 years (38–40).